Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619443 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07619443 is a Phase 1 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 30 participants.
The verdict
NCT07619443, a Phase 1 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Interventions
- DRUG Enlicitide
- DRUG MK-7262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-06 |
| Est. Completion | 2026-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07619443
The ClinicalTrials.gov registry entry for NCT07619443 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enlicitide is the first listed.
NCT07619443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07619443 about?
NCT07619443 is a clinical study titled "A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)". The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a singl...
What is the current status of trial NCT07619443?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07-06. Estimated completion is 2026-09-12.
What interventions are being tested in trial NCT07619443?
The interventions under investigation include: Enlicitide (DRUG), MK-7262 (DRUG).
Who is sponsoring clinical trial NCT07619443?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.